Plain-English translation of NCT07589517 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of cell therapy called dual-target CAR-NK cells, which are immune cells grown in the laboratory to recognize and attack colorectal cancer. These cells are designed to target specific markers on cancer cells while minimizing damage to healthy tissue. This medication is being studied as a potentially safer alternative to similar cell therapies that have been used for other cancers.
Colorectal cancer that has spread or cannot be removed by surgery often becomes resistant to standard treatments, leaving patients with limited options. This trial explores whether the treatment can help patients whose cancers have stopped responding to conventional therapy by using a newer approach that may have fewer serious side effects than related treatments.
You likely qualify if…
You likely don't qualify if…
You will first undergo chemotherapy to prepare your body, followed by an infusion of the laboratory-made immune cells. You will need to stay in the hospital or be closely monitored during the early period after the infusion. The study has two phases: a dose-escalation phase to find the safest dose, and an expansion phase to further test the most promising treatment approach. Your doctor will monitor you carefully for side effects and signs that the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China